Document Detail

Budesonide/Formoterol pressurized metered-dose inhaler.
MedLine Citation:
PMID:  18729536     Owner:  NLM     Status:  MEDLINE    
*The corticosteroid budesonide and the long-acting [beta]2-adrenoceptor agonist formoterol have been combined into a single pressurized metered-dose inhaler (pMDI) for use in patients aged > or =12 years with asthma. *In well designed 12-week clinical trials in patients with mild to moderate or moderate to severe persistent asthma, lung function improved to a significantly greater extent with twice-daily budesonide/formoterol pMDI 160 [micro]g/9 [micro]g or 320 [micro]g/9 [micro]g than with placebo or the same nominal dosage of either of the components alone. *Budesonide/formoterol pMDI was also associated with improvements from baseline in patient-reported asthma control, asthma symptom and asthma-related quality of life outcomes that were significantly greater than those with placebo and, for many endpoints, monotherapy with the individual components. *In a 52-week safety study, treatment with twice-daily budesonide/formoterol pMDI 320 [micro]g/9 [micro]g was associated with rapid and durable improvements in lung function and asthma control that were significantly greater than those with twice-daily budesonide pMDI 640 [micro]g monotherapy. *Budesonide/formoterol pMDI was well tolerated in clinical trials. Its overall adverse event profile is consistent with the known tolerability profiles of long-acting [beta]2-adrenoceptor agonist and inhaled corticosteroid therapy, and is similar to that shown with placebo.
Katherine A Lyseng-Williamson; Dene Simpson
Related Documents :
18729536 - Budesonide/formoterol pressurized metered-dose inhaler.
14217256 - Man under pressure.
15601196 - Pressure-induced colossal magnetocaloric effect in mnas.
21505356 - Perinatal inhibition of nf-kappab has long-term antihypertensive effects in spontaneous...
18218916 - Cerebrovascular responsiveness to steady-state changes in end-tidal co2 during passive ...
17474556 - Association between biomarkers of inflammation and left ventricular hypertrophy in mode...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  68     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2008  
Date Detail:
Created Date:  2008-08-27     Completed Date:  2009-01-12     Revised Date:  2013-06-11    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  1855-64     Citation Subset:  IM    
Wolters Kluwer Health | Adis, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Inhalation
Adrenal Cortex Hormones / administration & dosage,  pharmacokinetics,  therapeutic use*
Asthma / drug therapy*
Budesonide / administration & dosage,  pharmacokinetics,  therapeutic use*
Drug Combinations
Ethanolamines / administration & dosage,  pharmacokinetics,  therapeutic use*
Metered Dose Inhalers*
Randomized Controlled Trials as Topic
Treatment Outcome
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Drug Combinations; 0/Ethanolamines; 51333-22-3/Budesonide; 5ZZ84GCW8B/formoterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Short- versus long-course antibacterial therapy for community-acquired pneumonia : a meta-analysis.
Next Document:  Febuxostat.